Breaking out in a rash after exposure to sunlight is not uncommon – here’s what you need to know about sun allergy.

focusing on Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP). This progression surfaced as part of a current report on Form 8-K, offering important insights into the company ...

Disc Medicine, Inc. (NASDAQ: IRON) has announced its plans to commence an underwritten public offering of $200.0 million of ...

Stifel analysts increased their price target for Disc Medicine (NASDAQ:IRON) shares to $94.00, up from the previous $90.00. Currently trading at $57.07 with a market capitalization of $1.7 billion, ...

Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA earlier this week.

Disc intends to use the net proceeds from the offering to fund research and clinical development of its current or additional product candidates, to support the potential commercialization of ...

Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and potentially life-threatening disease caused by mutations that affect heme biosynthesis ...

an investigational treatment for erythropoietic protoporphyria or EPP. The FDA provided guidance on the design of the APOLLO post-marketing confirmatory trial, which will support an accelerated ...

The agreement, previously announced on January 13, 2025, aims to enable autonomous drone and unmanned aerial vehicle ("UAV”) technology by integrating Foresight's cutting-edge 3D perception solutions ...

Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021. Erythropoietic protoporphyria (EPP), including X-linked Protoporphyria (XLP), is a rare, debilitating and ...

Inclusion of patients aged 12+ with EPP including X-linked protoporphyria (XLP); and Double-blind, placebo-controlled study with ~150 patients randomized 1:1.